MedPath

To study the effect of Drug Nivolumab in patients with cancers.

Not Applicable
Conditions
Health Condition 1: C819- Hodgkin lymphoma, unspecified
Registration Number
CTRI/2022/04/042179
Lead Sponsor
Christian Medical College
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

i.Patients with primary progressive or relapsed Hodgkin lymphoma

ii.Signed and dated written informed consent by start date of Screening visit in accordance with GCP

Exclusion Criteria

i. Age <18years

ii. Pregnancy or lactation

iii. Hepatitis B, C or HIV

iv. Ejection fraction <40%

v. Total Bilirubin >3mg%

vi. Serum Creatinine > 2mg%

vii.ECOG performance score >3

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath